Colchicine: New Insights to an Old Drug

American Journal of Therapeutics

Volumn 22, Issue 5, 2015, Pages e151-e157

  Stack, John ^a   Ryan, John ^a   McCarthy, Geraldine ^b  

^a University College Cork   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

colchicine; gout; inflammasome; mechanism of action; toxicity

Indexed keywords

COLCHICINE; CYTOCHROME P450 3A4; INFLAMMASOME; INTERLEUKIN 1BETA; URATE; ANTIGOUT AGENT; CARRIER PROTEIN; CYTOCHROME P450 3A; NLRP3 PROTEIN, HUMAN; URIC ACID;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DISRUPTION; CRYSTAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GOUT; HUMAN; MICROTUBULE ASSEMBLY; MULTIPLE ORGAN FAILURE; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; TARGET CELL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG MONITORING; METABOLISM; PATHOPHYSIOLOGY;

CARRIER PROTEINS; COLCHICINE; CYTOCHROME P-450 CYP3A; DRUG MONITORING; GOUT; GOUT SUPPRESSANTS; HUMANS; INTERLEUKIN-1BETA; NEUTROPHILS; URIC ACID;

EID: 84941880512     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/01.mjt.0000433937.07244.e1     Document Type: Article

References (35)

1. Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8(Suppl 1):S1.
2. Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48:407-414.
3. Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008;10:218-227.
4. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516-521.
5. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229-265.
6. Lane T, Lachmann HJ. The emerging role of interleukin-1b in autoinflammatory diseases. Curr Allergy Asthma Rep. 2011;11:361-368.
7. Schorn C, Frey B, Lauber K, et al. Sodium overload and water influx activate the NALP3 inflammasome. J Biol Chem. 2011;286;35-41.
8. McCarty DJ. Urate crystals, inflammation, and colchicine. Arthritis Rheum. 2008;58:S20-S24.
9. Caviston JP, Holzbaur ELF. Microtubule motors at the intersection of trafficking and transport. Trends Cell Biol. 2006;16:530-537.
10. Ben-Chetrit E, Levy M. Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases? Med Hypotheses. 1998;51:377-380.
11. Cronstein BN, Molad Y, Reibman J, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995;96:994-1002.
12. Chia EW, Grainger R, Harper JL. Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br J Pharmacol. 2008;153:1288-1295.
13. Roberge CJ, Gaudry M, de M-edicis R, et al. Crystalinduced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest. 1993;92:1722-1729.
14. Martinon F, P-etrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237-241.
15. Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever. A controlled, doubleblind study. Ann Intern Med. 1974;81:792-794.
16. Dinarello CA, Wolff SM, Goldfinger SE, et al. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med. 1974;291:934-937.
17. Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med. 1974;291:932-934.
18. Ozen S, Bilginer Y, Aktay Ayaz N, et al. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38:516-518.
19. Neogi T. Interleukin-1 antagonism in acute gout: is targeting a single cytokine the answer? Arthritis Rheum. 2010;62: 2845-2849.
20. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987;17:301-304.
21. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312-1324.
22. TerkeltaubRA, FurstDE, BennettK, et al. High versus low dosing of oral colchicine for early acute gout flare: twentyfour-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dosecomparison colchicine study. Arthritis Rheum. 2010;62: 1060-1068.
23. Imazio M, Bobbio M, Cecchi E, et al. Colchicine as firstchoice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165:1987-1991.
24. Langevitz P, Livneh A, Neumann L, et al. Prevalence of ischaemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J. 2001;3:9-12.
25. Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39: 1458-1464.
26. Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404-410.
27. Imazio M, Trinchero R, Brucato A, et al. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placeo-controlled trial. Eur Heart J. 2010;31:2749-2754.
28. Imazio M, Brucato A, Ferrazzi P, et al. Colchicine reduces postoperative atrial fibrillation: results of the COlchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011;124: 2290-2295.
29. Imazio M, Belli R, Brucato A, et al. Rationale and design of the colchicine for prevention of the postpericardiotomy syndrome and postoperative atrial fibrillation (COPPS-2 trial): a randomized, placebo-controlled, multicentre study on the use of colchicine for the primary prevention of the postpericardiotomy syndrome, postoperative effusions and postoperative atrial fibrillation. Am Heart J. 2013; 166:13-19.
30. Ishii Y, Schuessler RB, Gaynor SL, et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation. 2005;111:2881-2888.
31. Rudolph V, Andrie RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med. 2010;16:470-474.
32. Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine. 2006;73:672-678.
33. Ben-Chetrit E, Scherrmann JM, Zylber-Katz E, et al. Colchicine disposition in patients with familial Mediterranean fever with renal impairment. J Rheumatol. 1994;21:710-713.
34. Terkeltaub RA, Furst DE, Digiacinto JL, et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63:2226-2237.
35. Wason S, Digiacinto JL, Davis MW. Effects of grapefruit and seville orange juices on the pharmacokinetic properties of colchicine in healthy subjects. Clin Ther. 2012;34: 2161-2173.